Chimeric Therapeutics Limited is trading 4% down at $0.07 on light, news-thin trading, extending recent volatility in this micro-cap biotech name.
-
The move appears driven by normal illiquid trading fluctuations rather than a specific catalyst, with no fresh ASX announcements or major company updates released in recent days.
-
The downward pressure comes despite a broadly risk-on macro backdrop, as indicated by stronger equity futures in the wider market.